Most people are more familiar with peptide drugs for weight loss or growth hormone than with peptide antivirals, but enfuvirtide, approved by the FDA more than two decades ago, remains a notable example of a peptide engineered to physically block a virus from entering human cells in the first place.

What It Is

Enfuvirtide is a synthetic 36-amino-acid peptide sold under the brand name Fuzeon. It was the first drug in its class, known as fusion inhibitors, approved for the treatment of HIV infection. Rather than interfering with the virus's replication machinery once it's already inside a cell, as most antiretroviral drugs do, enfuvirtide binds to a specific viral surface protein (gp41) and blocks the fusion step HIV needs to merge its membrane with a human immune cell and inject its genetic material.

Regulatory Status

Enfuvirtide received FDA approval in 2003 for use in combination with other antiretroviral agents in treatment-experienced patients with evidence of ongoing HIV replication despite prior therapy. It is not a first-line HIV treatment and was never intended to be one.

Why It's Not First-Line Therapy

Enfuvirtide has to be given as a twice-daily subcutaneous injection, which is a significantly heavier treatment burden than the once-daily oral combination pills that now form the backbone of standard HIV treatment. Injection-site reactions, including pain, redness, and nodules, are extremely common with enfuvirtide, occurring in a large majority of patients to some degree. Because effective, better-tolerated oral regimens became available in the years after enfuvirtide's approval, its practical use narrowed to a specific population: people with multidrug-resistant HIV who have limited remaining treatment options and need an additional active agent from a different mechanistic class to construct an effective regimen.

What the Evidence Shows

Enfuvirtide's approval was supported by randomized controlled human clinical trials in treatment-experienced patients, in which adding it to an existing failing regimen improved viral suppression compared to that regimen alone. This is a peptide with a genuinely well-established human efficacy and safety record, not a preclinical or animal-only evidence base; the tradeoffs involved are about convenience, tolerability, and its place in a modern treatment algorithm, not about whether it works.

Safety Considerations

Beyond the near-universal injection-site reactions, enfuvirtide has been associated with increased rates of bacterial pneumonia in some trials, and, like other HIV medications, requires monitoring in the context of a patient's full antiretroviral regimen and any other conditions they have. It's used exclusively under specialist medical supervision as part of a constructed treatment plan, never as a standalone or self-directed therapy.

The Bottom Line

Enfuvirtide illustrates something worth remembering about drug development generally: a drug's clinical importance doesn't always track with how widely it's used. It's a niche, twice-daily injectable reserved for a shrinking population of multidrug-resistant patients, but it also represents an entirely distinct antiviral mechanism, developed and validated in human trials, that remains a genuinely useful tool when other options run out.